Poplar Therapeutics
PrivateLast Round
Series A
Extension
Mar 3, 2026
Total Funding Raised
$140M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Poplar Therapeutics operates in Healthcare & Life Sciences and is based in Cambridge, Massachusetts. Its latest recorded funding round was a Series A Extension round in March 2026.
Poplar Therapeutics is a clinical-stage immunology company developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Poplar Therapeutics Comparables
Compare Poplar Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| IgGenix | 81% | |
| Mabylon AG | 77% | |
| United BioPharma | 70% |
For institutional investors. Book with your work email.
Poplar Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Mar 3, 2026 | ||||
| Series A | Jan 8, 2026 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Poplar Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Janus Henderson Group | Series A, Series A Extension |
| RA Capital Management | Series A, Series A Extension |
| Vida Ventures | Series A Extension, Series A |
| ArrowMark Partners | Series A, Series A Extension |
| Platanus Ventures | Series A |
| SR One | Series A Extension, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Mar 3, 2026
$45M round led by Janus Henderson Group.
- Jan 8, 2026
$50M Series A round completed.
For institutional investors. Book with your work email.
Poplar Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Poplar Therapeutics's valuation, stock price, and market status.
Is Poplar Therapeutics a public or private company?
Poplar Therapeutics is a private company.
What is the current stock price of Poplar Therapeutics?
Poplar Therapeutics is a private company, so its shares have no public market price. Caplight tracks Poplar Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Poplar Therapeutics worth (valuation)?
Valuation information for Poplar Therapeutics is not publicly available.
Can I buy Poplar Therapeutics stock?
Poplar Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Poplar Therapeutics's last funding round?
Poplar Therapeutics's most recent funding round was Series A Extension on March 3, 2026.
Who are the main investors in Poplar Therapeutics?
Key investors in Poplar Therapeutics include Janus Henderson Group, Vida Ventures, Platanus Ventures, SR One.
Will Poplar Therapeutics IPO soon?
No public IPO plans have been announced for Poplar Therapeutics.
How can I track Poplar Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Poplar Therapeutics's shares on secondary markets.